MAX and neuroblastoma: Utilizing a MYCN-amplified neuroblastoma xenograft tumor model, we could show that MYCMI-6 treatment significantly reduced MYCN:MAX interaction in tumor tissue, suggesting that MYCMI-6 reached and was active against its target in vivo (Fig. 7).